TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05775497

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Behavioral weight loss intervention (Online; Rx Weight Loss)
Description: Rx Weight Loss is a fully automated online behavioral obesity treatment that includes 3 core components: weekly online video lessons, submission of self-monitored weight, calorie intake, and activity data, and personalized automated feedback. Participants set goals for weight loss (e.g., 10%), daily calorie intake, and activity (e.g., 200 mins/week of moderate-to-vigorous intensity physical activity). Online lessons discuss healthy eating, physical activity, and behavioral skills (e.g., stimulus control, goal-setting, problem solving). To maintain participant engagement, lessons are interactive, use audio and video, and include experiential learning opportunities. Based on their progress, participants receive automated feedback that provides encouragement, praise for meeting goals, and constructive feedback. To enhance adherence, participants who do not view the weekly lesson or enter monitoring data receive e-mail reminders to re-engage.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Behavioral weight loss intervention (Online; Rx Weight Loss)
Description: Rx Weight Loss is a fully automated online behavioral obesity treatment that includes 3 core components: weekly online video lessons, submission of self-monitored weight, calorie intake, and activity data, and personalized automated feedback. Participants set goals for weight loss (e.g., 10%), daily calorie intake, and activity (e.g., 200 mins/week of moderate-to-vigorous intensity physical activity). Online lessons discuss healthy eating, physical activity, and behavioral skills (e.g., stimulus control, goal-setting, problem solving). To maintain participant engagement, lessons are interactive, use audio and video, and include experiential learning opportunities. Based on their progress, participants receive automated feedback that provides encouragement, praise for meeting goals, and constructive feedback. To enhance adherence, participants who do not view the weekly lesson or enter monitoring data receive e-mail reminders to re-engage.
Study: NCT06256835

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Rehabilitation treatment
Description: Both groups are given rehabilitation treatment. The main intervention measures included: 1) non-invasive ventilator treatment, generally at least once every night and typically not exceeding continuous daily usage.; 2) attention to feeding and sleeping positions, with a recommended sleeping position of lateral recumbent and the head of the bed raised by 20-30°; 3) swallowing function training, such as tongue muscle stretching training, assisted anterior jaw protrusion training, lemon ice stimulation to the soft palate, pharyngeal wall, etc., generally 5 days per week, twice per day, 5-20 minutes each time; 4) pulmonary ultrashort wave therapy, generally at least 2-3 times a week, and not more than once a day; 5) physical therapy, such as intensive training for gross motor functions including lifting the head, turning over, sitting, crawling, standing, etc., generally 3-5 days per week, 1-2 times per day, 5-20 min each time.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Rehabilitation treatment
Description: Both groups are given rehabilitation treatment. The main intervention measures included: 1) non-invasive ventilator treatment, generally at least once every night and typically not exceeding continuous daily usage.; 2) attention to feeding and sleeping positions, with a recommended sleeping position of lateral recumbent and the head of the bed raised by 20-30°; 3) swallowing function training, such as tongue muscle stretching training, assisted anterior jaw protrusion training, lemon ice stimulation to the soft palate, pharyngeal wall, etc., generally 5 days per week, twice per day, 5-20 minutes each time; 4) pulmonary ultrashort wave therapy, generally at least 2-3 times a week, and not more than once a day; 5) physical therapy, such as intensive training for gross motor functions including lifting the head, turning over, sitting, crawling, standing, etc., generally 3-5 days per week, 1-2 times per day, 5-20 min each time.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Myofascial Release Therapy
Description: Myofascial release, also known as fascial release or fascial manipulation, is a physical therapy used to treat muscle and fascial tissue tension or pain. It involves applying appropriate pressure and stretching to release tight fascia and soft tissues, improving blood circulation, alleviating pain, and promoting rehabilitation. Myofascial release therapy is commonly used to treat muscle spasms, chronic pain, skeletal and joint issues, among others.
Study: NCT06360042

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Adebrelimab plus Apatinib
Description: Adebrelimab 1200mg intravenously every 3 weeks plus Apatinib 250mg orally once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Adebrelimab plus Bevacizumab
Description: Adebrelimab 1200mg intravenously plus Bevacizumab 15 mg/kg intravenously every 3 weeks
Study: NCT06447025

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CTI-1601
Description: CTI-1601 is a recombinant fusion protein and is intended to deliver human frataxin, the protein deficient in Friedreich's ataxia
Study: NCT05526794

Intervention type: PROCEDURE
Intervention: Analgesic consumption
Description: 1 gr iv paracetamol for all patients with a VAS value of 2 or 3; for 4 and over, 1.5 mg/kg iv tramadol was administered additionally.

Intervention type: PROCEDURE
Intervention: Analgesic consumption
Description: 1 gr iv paracetamol for all patients with a VAS value of 2 or 3; for 4 and over, 1.5 mg/kg iv tramadol was administered additionally.

Intervention type: PROCEDURE
Intervention: Analgesic consumption
Description: 1 gr iv paracetamol for all patients with a VAS value of 2 or 3; for 4 and over, 1.5 mg/kg iv tramadol was administered additionally.
Study: NCT05794932

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Stress test
Description: Diagnostic Test:~* Maximum effort test (CPET) on a cycloergometer~* Leg muscle strength assessment~* Leg muscle mass, composition and water compartments (segmental bioelectrical impedance)~* Spirometry, arterial blood gaz, NO/CO transfer
Study: NCT05610995

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: SENSIUM Patch
Description: The SENSIUM device is a tool to monitor vital signs by applying a connected skin patch whose objective is to detect complications early. The health data is transmitted to the practitioner and in case of disturbance of the parameters, an alert is sent. The patient can be called for consultation or hospitalization if necessary. This device has been tested under real clinical conditions in surgical units. The continuous monitoring of vital signs resulted in earlier detection of sepsis, earlier administration of antibiotics, shorter average length of stay and lower 30-day readmission rates.
Study: NCT04903275

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Topical fluoride application and Laser irradiation
Description: Topical fluoride varnish application (Clinpro™ White Varnish 5% Sodium Fluoride, 3M ESPE, USA) of the vestibular surfaces of the left maxillary anterior teeth followed by laser irradiation with CO2-laser (Ultra Dream Pulse, DS_40U, Daeshin Enterprise, Seoul, South Korea), emission wavelength 10,600 nm, time on-100 μs, time off-40 ms; average power-0.73 W; peak power-292.73 W; speed of movement-2 mm/s; energy density with movements-5 J/cm2; tip-to-tissue distance-20 mm; tip diameter 700 μm; irradiation time-30 s.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Topical fluoride application
Description: Topical fluoride varnish application (Clinpro™ White Varnish 5% Sodium Fluoride, 3M ESPE, USA) of the vestibular surfaces of the left maxillary anterior teeth
Study: NCT04903444

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Artificial intelligence assistant system
Description: The endoscopists in the experimental group will be assisted by AI system, which can instruct the direction of guide wire and the position of stent placement in real time. The system is an non-invasive AI system .
Study: NCT06360042

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Camrelizumab plus Apatinib
Description: camrelizumab 200mg intravenously every 2 weeks plus Apatinib 250mg orally once daily
Study: NCT04709796

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: EmbryoGlue®, Vitrolife
Description: The intervention under study is the application of EmbryoGlue®, a class III medical device (CE Marked). EmbryoGlue® is a bicarbonate buffered medium containing recombinant human albumin, hyaluronan and gentamicin as an antibacterial agent.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Conventional Transfer
Description: The control arm is the conventional embryo transfer without Embryo glue medium
Study: NCT05026034

Intervention type: DEVICE
Intervention: non-invasive Cardiopulmonary Management (CPM) wearable device
Description: non-invasive Cardiopulmonary Management (CPM) wearable device with measures of congestion in heart failure

Intervention type: DEVICE
Intervention: non-invasive Cardiopulmonary Management (CPM) wearable device
Description: non-invasive Cardiopulmonary Management (CPM) wearable device with measures of congestion in heart failure

Intervention type: DEVICE
Intervention: non-invasive Cardiopulmonary Management (CPM) wearable device
Description: non-invasive Cardiopulmonary Management (CPM) wearable device with measures of congestion in heart failure

Intervention type: DEVICE
Intervention: non-invasive Cardiopulmonary Management (CPM) wearable device
Description: non-invasive Cardiopulmonary Management (CPM) wearable device with measures of congestion in heart failure
Study: NCT04848649

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Study arm
Description: Questionnaires, blood sample, skin (for psoriasis patients) or digestive (for IBD patients) biopsy and swab testing
Study: NCT04703842

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: SRD-001
Description: AAV1/SERCA2a
Study: NCT05886049

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biospecimen Collection
Description: Undergo collection of blood

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Bone Marrow Aspiration
Description: Undergo bone marrow aspiration and biopsy

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Bone Marrow Biopsy
Description: Undergo bone marrow aspiration and biopsy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cytarabine
Description: Given IV
Study: NCT06250127

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Modified 3D printed facemask
Description: modified 3D printed customized maxillary protraction facemask will be used for growing patients who have Cl. III malocclusion, hyrax expansion appliance and applying an elastic force of 300-500 gram per side for 12-14 hours per day. Treatment time 9 months.
Study: NCT05886049

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Daunorubicin
Description: Given IV

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Multigated Acquisition Scan
Description: Undergo MUGA

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Revumenib
Description: Given PO

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Transthoracic Echocardiography
Description: Undergo transthoracic ECHO
Study: NCT06201845

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise awareness training
Description: Group exercise training will consist of aerobic exercises including warm-up and cool-down exercises accompanied by music, and trunk strengthening training consisting of core exercises.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: physical activity awareness training
Description: In the physical activity awareness training, the benefits of exercises on systemic, psychological effects and general body health will be explained and they will be informed about different exercise practice.
Study: NCT06250127

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Conventional facemask appliance
Description: Conventional facemask appliance will be used for growing patients who have Cl. III malocclusion, hyrax expansion appliance and applying an elastic force of 300-500 gram per side for 12-14 hours per day. Treatment time 9 months.
Study: NCT04703842

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: SRD-001 matching placebo
Study: NCT05965791

Intervention type: DIAGNOSTIC_TEST
Intervention: Phalen's wrist flexion test
Description: The Phalen's test will be performed at different wrist flexion angles from 0 to 90 degrees.
Study: NCT06365684

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sodium zirconium cyclosilicate
Description: In the case of hyperkalemia patients will be treated with Sodium zirconium cyclosilicate to allow the continuation of potassium enriched diet. In case hyperkalemia arises in the control group, patients will be treated with Sodium zirconium cyclosilicate as well.
Study: NCT06269536

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: HRV biofeedback
Description: Daily deep paced breathing 3-times (minimum 7 minutes each) for 3 months
Study: NCT06068777

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rosmary
Description: inhale two drops of rosemary oil, from a gauze, for 3 minutes before the procedure of extraction of a primary molar

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lemongrass Oil
Description: inhale two drops of lemongrass oil, from a gauze, for three minutes before the procedure of extraction.
Study: NCT05453786

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SID1903
Description: Single oral administration of SID1903 after an overnight fast

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SID1903
Description: Single oral administration of SID1903 after an overnight fast

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SID1903-R1/SID1903-R2
Description: Single oral administration of SID1903-R1 and SID1903-R2 after an overnight fast
Study: NCT05256069

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Propranolol Pill
Description: Participants will receive a β-blockade (propranolol pill, 1 mg/kg dosed based on participant weight).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Participants will receive a placebo in pill form.
Study: NCT05093413

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Sleep deprivation
Description: Fully slept: Sleep habitual amount (i.e., go to sleep at habitual bedtime and wake up at habitual wake time) Sleep deprived: Reduce sleep by 50% (i.e., go to sleep at habitual bedtime and wake up early)

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Sleep deprivation
Description: Fully slept: Sleep habitual amount (i.e., go to sleep at habitual bedtime and wake up at habitual wake time) Sleep deprived: Reduce sleep by 50% (i.e., go to sleep at habitual bedtime and wake up early)
Study: NCT05453786

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SID1903-R1/SID1903-R2
Description: Single oral administration of SID1903-R1 and SID1903-R2 after an overnight fast
Study: NCT05307133

Intervention type: OTHER
Group type: OTHER
Intervention: Sleeve Gastreextomy
Description: The aim of the present study is to elucidate whether serum levels of oxytocin and sleeve gastrectomy induced weight loss are correlated in pre-menopausal morbidly obese women.
Study: NCT04746079

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Positive Imagery Therapy
Description: Perform procedural sedation with slow push of ketamine, 1.5mg/kg, over thirty seconds while reading the Positive Imagery Therapy.
Study: NCT05843045

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Indoor Air Quality Mitigation
Description: Mitigation of indoor air quality with use of smart thermostat, smart bath fan control, and high quality furnace filters
Study: NCT04852146

Intervention type: PROCEDURE
Intervention: Electronic feedback
Description: Feedbacks have been identified as one of the most effective interventions to improve practices and organisations in health care institutions. It is also a tool for facilitating and coordinating practice registers, improving the contribution of data producers and the quality of data.

Intervention type: PROCEDURE
Intervention: Electronic feedback
Description: Feedbacks have been identified as one of the most effective interventions to improve practices and organisations in health care institutions. It is also a tool for facilitating and coordinating practice registers, improving the contribution of data producers and the quality of data.
Study: NCT04994054

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: silkworms (Bombyx mori L.) pupae extracts group
Description: silkworms (Bombyx mori L.) pupae extracts 2,400 mg/day for 12 weeks

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo group
Description: Placebo 2,400 mg/day for 12 weeks
Study: NCT04683159

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Brimonidine Tartrate 0.15% Oph Soln
Description: 1 drop of brimonidine 0.15% (\~0.05mL) 15 minutes prior to surgery

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Brimonidine Tartrate 0.025% Oph Soln
Description: 1 drop of brimonidine 0.025% (\~0.05mL) 15 minutes prior to surgery
Study: NCT05309980

Intervention type: OTHER
Intervention: standard of care
Description: retrospective study : standard of care

Intervention type: OTHER
Intervention: standard of care
Description: retrospective study : standard of care
Study: NCT05965219

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Emraclidine
Description: Emraclidine tablets.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Emraclidine
Description: Emraclidine tablets.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Emraclidine
Description: Emraclidine tablets.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Itraconazole
Description: Itraconazole oral solution.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carbamazepine
Description: Carbamazepine tablets.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin
Description: Metformin tablets.
Study: NCT05453084

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise Program
Description: The intervention includes an individualized exercise program in terms of Frequency, Intensity, Time, Type, Volume and Progression (FITT-VP).
Study: NCT05045703

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Vitamin A palmitate
Description: Vitamin A palmitate, 15,000 IU daily for 4 months
Study: NCT05565391

Intervention type: DRUG
Intervention: Elranatamab
Description: BCMA-CD3 bispecific antibody

Intervention type: DRUG
Intervention: Standard of care
Description: Standard of care
Study: NCT05437341

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: bi-4SCAR PSMA/CD70 T cells
Description: Infusion of bi-4SCAR PSMA/CD70 T cells at 10\^6 cells/kg body weight via IV
Study: NCT06142461

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Gardasil
Description: Human Papillomavirus Quadrivalent (Types 6, 11, 16, and 18) Vaccine, Recombinant Pre-filled syringe, 0.5mL dose volume

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gardasil
Description: Human Papillomavirus Quadrivalent (Types 6, 11, 16, and 18) Vaccine, Recombinant Needle-free intramuscular injection, 0.5mL dose volume

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gardasil
Description: Human Papillomavirus Quadrivalent (Types 6, 11, 16, and 18) Vaccine, Recombinant Needle-free intradermal injection, 0.2mL dose volume

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PharmaJet Stratis® Needle-Free Injection System
Description: 0.5mL dose injection

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PharmaJet Tropis® Needle-Free Injection System
Description: 0.1mL dose injection
Study: NCT05873517

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Immediate Narrative Exposure Therapy (NET)+
Description: The basis of this intervention is adapted Narrative Exposure Therapy (NET)+. All participants receive 4-8 active NET+ sessions, including a psychoeducational session.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Waitlist + NET+
Description: Waitlist control group participants receive 1 psychoeducational sessions and will be added to a waitlist; waitlist control group participants randomly selected from the waitlist be offered the opportunity to receive the active intervention (NET+).
Study: NCT04872582

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PD-1 Immune Checkpoint Inhibitor Combined With Bevacizumab
Description: combined
Study: NCT05112458

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cope 360 mobile health application
Description: Cope 360 is a mHealth (mobile health) app designed to support caregivers of children with cancer with symptom tracking, medication management, and emergency preparedness. We will evaluate Cope 360 via a pilot, randomized control trial in which some caregivers will receive the app and some will not. The purpose of this study is to assess: 1) feasibility of caregiver use over extended period of time, 2) acceptability of the mHealth tool by caregivers in a real-world setting, 3) impact of the mHealth tool on caregiver self-efficacy, mastery of caregiving skills/knowledge, and caregiver stress, and 4) effect on healthcare utilization of the child with cancer (i.e. preliminary data about sick visits and ED encounters).

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Usual care
Description: Caregivers of children with cancer will receive the usual clinical care provided to our patient population.
Study: NCT06376214

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dratumumab / Hyaluronidase Injection [Darzalex Faspro]
Description: Daratumumab will be administered at the FDA-approved dose of 16mg/kg as an intravenous infusion.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dratumumab / Hyaluronidase Injection [Darzalex Faspro]
Description: Daratumumab will be administered at the FDA-approved dose of 16mg/kg as an intravenous infusion.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dratumumab / Hyaluronidase Injection [Darzalex Faspro]
Description: Daratumumab will be administered at the FDA-approved dose of 16mg/kg as an intravenous infusion.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pomalidomide 4 MG
Description: Patients received oral pomalidomide on days 1-21 of a 28-days cycle from cycle 1 to 6.